Filing Details
- Accession Number:
- 0000950170-24-114787
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-10-15 18:00:06
- Reporting Period:
- 2024-10-13
- Accepted Time:
- 2024-10-15 18:00:06
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1674416 | Crispr Therapeutics Ag | CRSP | Biological Products, (No Disgnostic Substances) (2836) | 473173478 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1708172 | R. James Kasinger | C/O Crispr Therapeutics 105 West First Street Boston MA 02127 | General Counsel And Secretary | No | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Shares | Acquisiton | 2024-10-13 | 2,113 | $0.00 | 63,686 | No | 4 | M | Direct | |
| Common Shares | Disposition | 2024-10-14 | 1,089 | $46.28 | 62,597 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Shares | Restricted Stock Units | Disposition | 2024-10-13 | 2,113 | $0.00 | 2,113 | $0.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 4,227 | No | 4 | M | Direct |
Footnotes
- Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.
- Includes 399 shares acquired under the CRISPR Therapeutics AG 2016 Employee Stock Purchase Plan.
- Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person.
- This restricted stock unit award was granted on October 13, 2023 with respect to 6,340 Common Shares, with (i) one third of the shares vesting on October 13, 2024, (ii) one third of the shares vesting on October 13, 2025, and (iii) one third of the shares vesting on October 13, 2026.
Billionaire Hedge Funds
